about
SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in ratsHeterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists.Activity of opioid ligands in cells expressing cloned mu opioid receptorsThe G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub componentsThe analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulationThe receptor concept: pharmacology's big ideaSynthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-positionInternational Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsGaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessorsHeterotrimeric G proteins precouple with G protein-coupled receptors in living cells.Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradoxCo-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatumA simple method for quantifying functional selectivity and agonist biasActivation of G protein-coupled receptors: beyond two-state models and tertiary conformational changes.Allosteric regulation of G protein-coupled receptor activity by phospholipids.Bihelix: Towards de novo structure prediction of an ensemble of G-protein coupled receptor conformations.Binding mode prediction of conformationally restricted anandamide analogs within the CB1 receptor.Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates.Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.Membrane model for the G-protein-coupled receptor rhodopsin: hydrophobic interface and dynamical structureAstrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophreniaSeven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Beyond desensitization: physiological relevance of arrestin-dependent signaling.The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells.A signal transduction pathway model prototype I: From agonist to cellular endpoint.Inverse agonism and its therapeutic significance.The potential for selective pharmacological therapies through biased receptor signalingLigand-induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its carboxyl-terminal tail.Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoidsInfluence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys.Extended pharmacological profiles of rat P2Y2 and rat P2Y4 receptors and their sensitivity to extracellular H+ and Zn2+ ions.Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes.G-protein-coupled receptors: past, present and future.Is there a SERT-ain association with IBS?The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors.Mu-opioid receptor desensitization: is morphine different?The Janus faces of adrenoceptors: factors controlling the coupling of adrenoceptors to multiple signal transduction pathways.Alpha-2 adrenoceptor subtypes: are more better?Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2
P2860
Q21262960-D7DC81DE-6F7A-4E5E-A105-F30F156A4760Q24535863-7EC6D1E3-3358-41E7-A9B9-3E99992F0738Q24540272-F999F0D9-BB0B-4CB9-B4BF-8FF476DAC3A4Q24564171-0202ED21-0FEA-49FA-98C8-5267AECA527BQ24648701-97D1D3B3-1C7E-4DE7-A426-045C437C0765Q24670242-13DA45F5-E01E-4925-87C7-C9F772F050E0Q24681800-34BC6144-4240-40FB-A290-31FD4F83069FQ26827568-41705DC2-358B-4F0D-934C-6BE0D3ECDBFDQ27005640-39D9C4EB-875F-42B2-A8C8-0D93EC75392EQ27863906-41595F21-B89E-4FDA-84B2-09DD3DF3D9B5Q28507610-52B72568-D387-4F12-BD8F-24A119333FA0Q28567681-DED7D166-20B7-4ED5-9B49-6C02822F2E72Q28728741-A08D7657-F5B4-462A-8D2F-CF2F4970C717Q30364526-11B92FE1-19CA-4F55-868E-913FB3D74AB3Q30381399-9767B063-EDB1-45F6-BD85-654CE1EF9AEFQ30410723-E3CB1CB9-D26C-42F7-92B8-537FD82B723CQ30481613-71F1AA20-D366-4824-8685-0C27CBB97CE6Q30655924-DE4889E1-2C56-4E9F-89EF-DACA2A5D4C8DQ30724397-0325E211-140E-4972-8B2F-00E1CB9A296AQ33200121-B853405F-9537-4E3D-A8AD-81340F149088Q33804875-6646AC0A-5BD9-4864-9BA8-4EF97591CAD2Q33890786-37283FDB-1D65-4FB1-8980-053FDA3A6234Q33890802-38BBE7D7-90FD-4B86-BEA3-9C58C73FAA32Q34127977-BE301F17-B759-4DC8-B40D-7119C34B24F6Q34186954-F2DCC830-D273-414F-BC5A-913117C40B81Q34226789-5ABECD09-7168-4466-90EC-2ACB9BD2D195Q34402658-22E6819D-DF23-4B67-8038-F712BA998C1CQ34438861-EA129C66-6DDB-4708-B516-6D4DF3D7306CQ34565057-014AD625-F0EB-4FDE-9F9B-6F1B7E9AE0FCQ34636231-1B52FBF7-81A5-4E02-877A-EDFCB16844E5Q34762698-D1A2DD44-D1EA-41E1-B48F-43A6D6E03AEDQ35045909-9F92A6D0-FA4A-4FDF-874D-69AC1B70098EQ35048608-4A7B331D-12E7-4884-A110-F309AB330439Q35566599-997A6995-473A-4A5D-83B7-1978089502D0Q35596897-B0D64E79-03EA-4450-B98B-FF76D4B68089Q35911754-AA901DBF-3064-4897-9F77-FFD2980E963BQ35927616-5167128E-D0E9-4A33-90F8-ED468B7CE275Q35964839-F060FCA8-B1CC-493C-B69B-2058FF0B1F58Q36012348-93AB9ADF-5887-4D04-851F-B8EA6DFAC73BQ36016398-FF89EA5F-9C7E-466E-8C94-FF83455A28EB
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Drug efficacy at G protein-coupled receptors.
@ast
Drug efficacy at G protein-coupled receptors.
@en
Drug efficacy at G protein-coupled receptors.
@nl
type
label
Drug efficacy at G protein-coupled receptors.
@ast
Drug efficacy at G protein-coupled receptors.
@en
Drug efficacy at G protein-coupled receptors.
@nl
prefLabel
Drug efficacy at G protein-coupled receptors.
@ast
Drug efficacy at G protein-coupled receptors.
@en
Drug efficacy at G protein-coupled receptors.
@nl
P1476
Drug efficacy at G protein-coupled receptors.
@en
P2093
Terry Kenakin
P304
P356
10.1146/ANNUREV.PHARMTOX.42.091401.113012
P577
2002-01-01T00:00:00Z